Skip to main content

Table 1 Demographic and clinical features

From: Brain microglia activation and peripheral adaptive immunity in Parkinson’s disease: a multimodal PET study

 

Healthy control

Parkinson’s disease

P

Healthy control

Parkinson’s disease

High-affinity binders

Mix-affinity binders

No.

22

22

1

2

Age

58.91 ± 9.78

59.27 ± 11.96

0.913

59

60, 66

Gender (M/F)

10/12

15/7

0.128

0/1

1/1

MDS-UPDRS III scores

0.41 ± 1.33

21.23 ± 10.14

< 0.0001

0

11, 5

GDS

6.09 ± 6.29

6.27 ± 5.44

0.680a

2

7, 16

MMSE

28.45 ± 1.79

26.95 ± 6.35

0.236

30

28, 30

RBDQ-HK

6.95 ± 8.28

12.73 ± 14.71

0.163a

5

4, 9

LEDD

508.33 ± 239.7

0, 0

Dose (18F-FP-DTBZ)

283.82 ± 60.34

298.00 ± 67.01

0.469

346

267, 253

Dose (18F-PRB06)

348.14 ± 19.61

353.35 ± 21.54

0.430

360

373, 332

  1. GDS Geriatric Depression Scale, MDS-UPDRS III MDS-Unified Parkinson’s Disease Rating Scale motor scores, MMSE Mini-Mental State Examination, MoCA Montreal Cognitive Assessment, P p-value, RBDQ-HK REM Sleep Behavior Disorder Questionnaire-Hong Kong, SUVR standardized uptake value ratio
  2. aCalculated with Mann–Whitney test